Hansa

Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma

Retrieved on: 
Friday, September 1, 2023
Swiss Federal Institute of Technology, Swiss, Braunschweig, Scripps Research, Therapy, Biopharmaceutical, Ibete, Anticalin, CSO, Institute of technology, Biotechnology, Hansa, United States Air Force Scientific Advisory Board, Research, Science, Boehringer Ingelheim, Natural science, Executive Committee, Immunoglobulin G, Walter, Biology, Ghassan Hitto, Research fellow, Industrial Affairs Committee (Iceland), Technical University of Braunschweig, Swiss Federal Institute of Aquatic Science and Technology, Fine chemical, Sanofi

LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.

Key Points: 
  • LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.
  • Dr. Kaufmann joins Hansa from Pieris Pharmaceuticals where he has served as Chief Scientific Officer since 2019.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "We are thrilled to welcome Hitto to Hansa at this pivotal time.
  • Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019.

Dr. Hitto Kaufmann appointed Chief Scientific Officer of Hansa Biopharma

Retrieved on: 
Friday, September 1, 2023
Swiss Federal Institute of Technology, Swiss, Braunschweig, Scripps Research, Therapy, Biopharmaceutical, Ibete, Anticalin, CSO, Institute of technology, Biotechnology, Hansa, United States Air Force Scientific Advisory Board, Research, Science, Boehringer Ingelheim, Natural science, Executive Committee, Immunoglobulin G, Walter, Biology, Ghassan Hitto, Research fellow, Industrial Affairs Committee (Iceland), Technical University of Braunschweig, Swiss Federal Institute of Aquatic Science and Technology, Fine chemical, Sanofi

LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.

Key Points: 
  • LUND, Sweden, Sept. 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Dr. Hitto Kaufmann has been appointed as Hansa's Chief Scientific Officer (CSO) effective 1 December 2023.
  • Dr. Kaufmann joins Hansa from Pieris Pharmaceuticals where he has served as Chief Scientific Officer since 2019.
  • Søren Tulstrup, President and CEO, Hansa Biopharma said, "We are thrilled to welcome Hitto to Hansa at this pivotal time.
  • Dr. Hitto Kaufmann has served as Chief Scientific Officer at Pieris Pharmaceuticals since 2019.

Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation

Retrieved on: 
Thursday, June 1, 2023
Face, Hansa, Hope, Antibody, Dialysis, Nephrology, Patient, Kidney transplantation, UZ Leuven, Transplant, Kidney, Dentistry

LUND, Sweden, June 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained reimbursement in Belgium for its first-in-class treatment, Idefirix, for the desensitization treatment of highly sensitized adult patients prior to kidney transplant from a deceased donor.

Key Points: 
  • LUND, Sweden, June 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained reimbursement in Belgium for its first-in-class treatment, Idefirix, for the desensitization treatment of highly sensitized adult patients prior to kidney transplant from a deceased donor.
  • Idefirix is available for eligible highly sensitized patients starting today, June 1, 2023.
  • Idefirix is the first and only product approved for use in highly sensitized patients waiting for a kidney transplant in Belgium.
  • Including Belgium, we now have positive access and reimbursement decisions in twelve countries in Europe – a testament to our commitment to ensure access to Idefirix for highly-sensitized patients waiting for a kidney transplant.

Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies

Retrieved on: 
Thursday, April 27, 2023
Nerve, Priority, Deafness, Hansa, Crigler–Najjar syndrome, Research, AAV, Trial of the century, Intellectual, Paralysis, EMA, Muscle weakness, Patient, Lethargy, MAA, Lance, BLA, DSM-IV codes, Safety, Pharmaceutical industry, Vaccine

The presence of circulating NAbs today excludes patients from entering clinical studies with potentially curative gene therapy treatments and from future access to approved gene therapies.

Key Points: 
  • The presence of circulating NAbs today excludes patients from entering clinical studies with potentially curative gene therapy treatments and from future access to approved gene therapies.
  • This research collaboration further validates Hansa's commitment in gene therapy and underscores the important role that our antibody-cleaving enzyme technology can play in ensuring that even more patients can benefit from life-saving gene therapies".
  • Through the collaboration announced today, patients with Crigler-Najjar and pre-formed antibodies to AAV8 will be enrolled in a study with similar design where imlifidase is evaluated as a pre-treatment to enable gene therapy treatment with GNT-0003.
  • Crigler-Najjar syndrome is an ultra-rare disease affecting less than one case per one million people per year.1
    Frédéric Revah, CEO, Genethon added: "Patients with pre-existing neutralizing antibodies against AAV vectors cannot today benefit from gene therapy.

Hansa Biopharma and Genethon announce collaboration to develop imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies

Retrieved on: 
Thursday, April 27, 2023
Nerve, Priority, Deafness, Hansa, Crigler–Najjar syndrome, Research, AAV, Trial of the century, Intellectual, Paralysis, EMA, Muscle weakness, Patient, Lethargy, MAA, Lance, BLA, DSM-IV codes, Safety, Pharmaceutical industry, Vaccine

The presence of circulating NAbs today excludes patients from entering clinical studies with potentially curative gene therapy treatments and from future access to approved gene therapies.

Key Points: 
  • The presence of circulating NAbs today excludes patients from entering clinical studies with potentially curative gene therapy treatments and from future access to approved gene therapies.
  • This research collaboration further validates Hansa's commitment in gene therapy and underscores the important role that our antibody-cleaving enzyme technology can play in ensuring that even more patients can benefit from life-saving gene therapies".
  • Through the collaboration announced today, patients with Crigler-Najjar and pre-formed antibodies to AAV8 will be enrolled in a study with similar design where imlifidase is evaluated as a pre-treatment to enable gene therapy treatment with GNT-0003.
  • Crigler-Najjar syndrome is an ultra-rare disease affecting less than one case per one million people per year.1
    Frédéric Revah, CEO, Genethon added: "Patients with pre-existing neutralizing antibodies against AAV vectors cannot today benefit from gene therapy.

Hansa Biopharma interim report January-March 2023

Retrieved on: 
Thursday, April 20, 2023
Inflammation, International, CET, Senior, Hansa, Hope, SOC, Confidant, Patient, Immunoglobulin G, GBS, Kidney, Kidney transplantation, CFO, Immunology, Rare, Transplant, News, Peripheral nervous system, Management, Dentistry, Pharmaceutical industry, Nursing, Internet service provider, Pfizer

Søren Tulstrup, President and CEO of Hansa Biopharma, comments

Key Points: 
  • Søren Tulstrup, President and CEO of Hansa Biopharma, comments
    "Hansa's commercial efforts for Idefirix® in Europe continue to progress as planned.
  • H1 2023            Anti-GBM Phase 3: First patient enrolled
    H2 2023            Long-term follow-up study in kidney transplantation: 5-year data readout
    H2 2023            AMR Phase 2: Full data readout
    H2 2023            GBS Phase 2: First data readout
    Hansa Biopharma will host a telephone conference today Thursday April 20, 2023, 14:00 CET / 8:00am EST.
  • The presentation will be held in English and be hosted by Hansa Biopharma's CEO, Søren Tulstrup, and CFO, Donato Spota.
  • To participate in the telephone conference, please use the dial-in details provided below:
    The interim report and latest investor presentation can be downloaded from our web:
    Investor road show presentation Q1, 2023 https://www.hansabiopharma.com/investors/presentations/
    This is information that Hansa Biopharma AB is obliged to make public pursuant to the Securities Markets Act.

Hansa Biopharma announces positive reimbursement decision in Spain for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation

Retrieved on: 
Wednesday, March 29, 2023
EU, CET, Vall d'Hebron University Hospital, Vall, Hansa, Person, Teaching hospital, Kidney transplantation, EMA, Nephrology, Patient, Nuevos Ministerios, Kidney, Transplant, News, Pharmaceutical industry, Dentistry, Health

The reimbursement approval of Idefirix® in Spain is another important step in this direction, as it now allows highly sensitized patients to be desensitized using Idefirix®, enabling a potentially lifesaving kidney transplant."

Key Points: 
  • The reimbursement approval of Idefirix® in Spain is another important step in this direction, as it now allows highly sensitized patients to be desensitized using Idefirix®, enabling a potentially lifesaving kidney transplant."
  • Of almost 4000 patients registered on the waiting list for a kidney transplant in Spain at the end of 20212, up to one in five (20%)3 are classified as highly sensitized.
  • "Many highly sensitized patients are still disadvantaged and in urgent need of more personalized and innovative desensitization options that can enable incompatible kidney transplantation.
  • This is information that Hansa Biopharma AB is obliged to make public pursuant to the EU Market Abuse Regulation.

Matthew Shaulis appointed Chief Commercial Officer and US President of Hansa Biopharma

Retrieved on: 
Friday, March 3, 2023
Schering-Plough, Hansa, Popular Executive Committee of Valencia, Immunology, Teva, Senior, Acquisition, Executive Committee, Inflammation, Johnson & Johnson, Management, Pfizer, Cephalon

LUND, Sweden, March 3, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew Shaulis will join the company effective 16 March as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma, Inc.

Key Points: 
  • LUND, Sweden, March 3, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (NASDAQ Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, announced today that Matthew Shaulis will join the company effective 16 March as Chief Commercial Officer and President of the U.S. affiliate, Hansa Biopharma, Inc.
  • He will report to President and CEO Søren Tulstrup and join the Executive Committee.
  • I would like to thank and congratulate Henk Doude van Troostwijk, who is moving into a new role as Vice President, Commercial Excellence, for his many contributions."
  • I'm looking forward to partnering across the enterprise to build out the U.S. organization and advance the global commercial priorities."

Hansa Biopharma announces positive reimbursement decision for Idefirix® (imlifidase) in the Czech Republic

Retrieved on: 
Monday, January 2, 2023
EMA, Quality of life, Mortality, Antibody, Priority, Medical research, Transplant, Patient, European, Nasdaq Stockholm, Dialysis, Kidney transplantation, Chronic kidney disease, Veni, vidi, vici, Medication package insert, Degenerative disease, Hospital, Kidney, Immunoglobulin G, Risk, Medicine, Safety, Kidney failure, ESRD, European Medicines Agency, State, Kidney disease, European Marketing Research Centre, Survival, Drug, Czech Republic, Human leukocyte antigen, Research, Cancer, DSA, Hansa, NIH, Health insurance, Dentistry, Pharmaceutical industry, Medical device, Agency

"We are very pleased to see that Idefirix® is now reimbursed in the Czech Republic for the treatment of highly sensitized kidney patients.

Key Points: 
  • "We are very pleased to see that Idefirix® is now reimbursed in the Czech Republic for the treatment of highly sensitized kidney patients.
  • These patients have a serious disease burden and unmet needs and this decision is a significant milestone for them", says Søren Tulstrup, President and CEO, Hansa Biopharma.
  • "For Hansa, this decision is well aligned with  our vision: A world where patients with rare immunologic diseases can lead long and healthy lives."
  • Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S.

Hansa Biopharma announces positive reimbursement decision in Italy for Idefirix® (imlifidase) as desensitization treatment for highly sensitized patients in kidney transplantation

Retrieved on: 
Thursday, December 8, 2022
NIH, Immunoglobulin G, Kidney transplantation, Dialysis, ESRD, European Medicines Agency, Italian Medicines Agency, EMA, Patient, Cancer, DSA, Research, Hlas, Nasdaq Stockholm, Kidney disease, Degenerative disease, Medicine, Human leukocyte antigen, Veni, vidi, vici, Antibody, Survival, Kidney, Hansa, Medication package insert, State, Safety, Kidney failure, European, Chronic kidney disease, European Marketing Research Centre, Transplant, Risk, Dentistry, Pharmaceutical industry, Medical device, Agency

The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix to enable kidney transplantation.

Key Points: 
  • The decision by the Italian Medicine Agency (AIFA) provides highly sensitized patients in Italy with the opportunity to receive Idefirix to enable kidney transplantation.
  • By the time the body starts to synthesize new IgG, the patient will be receiving post transplant immunosuppressive therapy to reduce the risk of organ rejection.
  • Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions.
  • Hansa has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients.